利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.02 秒)

    Method and compositions for treatments of cancers
    1.
    发明授权
    Method and compositions for treatments of cancers 有权
    治疗癌症的方法和组合物

    公开(公告)号：US06231536B1

    公开(公告)日：2001-05-15

    申请号：US09316226

    申请日：1999-05-21

    申请人： M. Rigdon Lentz

    发明人： M. Rigdon Lentz

    IPC分类号： A61M3700

    CPC分类号： A61K35/14 ,  A61K31/00 ,  A61K31/337 ,  A61K31/454 ,  A61K31/555 ,  A61K31/704 ,  A61K35/16 ,  A61K38/18 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/196 ,  A61K41/00 ,  A61K41/0019 ,  A61M1/34 ,  A61M1/342 ,  A61M1/3441 ,  A61M1/3472 ,  A61M1/3482 ,  A61M1/3681 ,  A61M2202/0417 ,  A61M2205/50 ,  A61M2205/75 ,  A61N5/1028 ,  B01D15/00 ,  B01D29/50 ,  B01D37/00 ,  B01D61/02 ,  A61K2300/00

    摘要： A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF. This provides a basis for an improved effect when combined with any treatment that enhances cytokine activity against the tumors, for example, treatments using alkylating agents, doxyrubicin, carboplatinum, cisplatinum, and taxol. Alternatively, the ultrapheresis treatment can be combined with local chemotherapy, systemic chemotherapy, and/or radiation.

    摘要翻译： 一种治疗癌症的方法是使用超级血液分离法，精制以除去小于120,000道尔顿分子量的化合物，然后施用替代液，以刺激患者的免疫系统攻击实体瘤。 在优选实施例中，使用孔径为0.02至0.05微米，分子量截留值为120,000道尔顿的毛细管超滤器将患者超薄，足以过滤一个血液体积。 优选的替代液体是超分离的正常血浆。 患者优选每天治疗三周，进行诊断测试以证实肿瘤已经收缩，然后重复治疗方案。 治疗优选与替代疗法组合，例如用抗血管生成化合物，一种或多种细胞因子如TNF，γ干扰素或IL-2或促凝血剂化合物的治疗。 治疗增加内源性，局部水平的细胞因子，如TNF。 当提供增强细胞因子对肿瘤活性的治疗，例如使用烷化剂，多柔比星，卡铂，顺铂和紫杉醇的治疗时，这提供了改善效果的基础。 或者，超单位治疗可以与局部化疗，全身化学疗法和/或辐射结合。

    Method and system to remove cytokine inhibitor in patients
    2.
    发明授权
    Method and system to remove cytokine inhibitor in patients 有权
    消除细胞因子抑制剂的方法和系统

    公开(公告)号：US08197430B1

    公开(公告)日：2012-06-12

    申请号：US09709045

    申请日：2000-11-10

    申请人： M. Rigdon Lentz

    发明人： M. Rigdon Lentz

    IPC分类号： A61M37/00 ,  C02F1/00 ,  B01D37/00 ,  A61K45/00 ,  A61K39/395

    CPC分类号： A61K31/00 ,  A61K31/337 ,  A61K31/555 ,  A61K31/704 ,  A61K41/00 ,  A61K41/0019 ,  A61K2039/505 ,  A61M1/34 ,  A61M1/342 ,  A61M1/3441 ,  A61M1/3468 ,  A61M1/3472 ,  A61M1/3482 ,  A61M1/3496 ,  A61M2202/0417 ,  C07K16/2878 ,  C07K2317/76

    摘要： A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF. This provides a basis for an improved effect when combined with any treatment that enhances cytokine activity against the tumors, for example, treatments using alkylating agents, doxyrubicin, carboplatinum, cisplatinum, and taxol. Alternatively, the ultrapheresis treatment can be combined with local chemotherapy, systemic chemotherapy, and/or radiation.

    摘要翻译： 一种治疗癌症的方法是使用超级血液分离法，精制以除去小于120,000道尔顿分子量的化合物，然后施用替代液，以刺激患者的免疫系统攻击实体瘤。 在优选实施例中，使用孔径为0.02至0.05微米，分子量截留值为120,000道尔顿的毛细管超滤器将患者超薄，足以过滤一个血液体积。 优选的替代液体是超分离的正常血浆。 患者优选每天治疗三周，进行诊断测试以证实肿瘤已经收缩，然后重复治疗方案。 治疗优选与替代疗法组合，例如用抗血管生成化合物，一种或多种细胞因子如TNF，γ干扰素或IL-2或促凝血剂化合物的治疗。 治疗增加内源性，局部水平的细胞因子，如TNF。 当提供增强细胞因子对肿瘤活性的治疗，例如使用烷化剂，多柔比星，卡铂，顺铂和紫杉醇的治疗时，这提供了改善效果的基础。 或者，超单位治疗可以与局部化疗，全身化学疗法和/或辐射结合。

    Method and system to remove cytokine inhibitors in patients
    3.
    发明授权
    Method and system to remove cytokine inhibitors in patients 有权
    消除患者细胞因子抑制剂的方法和系统

    公开(公告)号：US08133490B2

    公开(公告)日：2012-03-13

    申请号：US11929340

    申请日：2007-10-30

    申请人： M. Rigdon Lentz

    发明人： M. Rigdon Lentz

    IPC分类号： A61K38/19 ,  C07K16/24 ,  C07K14/52 ,  C07K16/30 ,  C07K14/715

    CPC分类号： A61K31/00 ,  A61K31/337 ,  A61K31/555 ,  A61K31/704 ,  A61K41/00 ,  A61K41/0019 ,  A61K2039/505 ,  A61M1/34 ,  A61M1/342 ,  A61M1/3441 ,  A61M1/3468 ,  A61M1/3472 ,  A61M1/3482 ,  A61M1/3496 ,  A61M2202/0417 ,  C07K16/2878 ,  C07K2317/76

    摘要： A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF. This provides a basis for an improved effect when combined with any treatment that enhances cytokine activity against the tumors, for example, treatments using alkylating agents, doxyrubicin, carboplatinum, cisplatinum, and taxol. Alternatively, the ultrapheresis treatment can be combined with local chemotherapy, systemic chemotherapy, and/or radiation.

    摘要翻译： 一种治疗癌症的方法是使用超级血液分离法，精制以除去小于120,000道尔顿分子量的化合物，然后施用替代液，以刺激患者的免疫系统攻击实体瘤。 在优选实施例中，使用孔径为0.02至0.05微米，分子量截留值为120,000道尔顿的毛细管超滤器将患者超薄，足以过滤一个血液体积。 优选的替代液体是超分离的正常血浆。 患者优选每天治疗三周，进行诊断测试以证实肿瘤已经收缩，然后重复治疗方案。 治疗优选与替代疗法组合，例如用抗血管生成化合物，一种或多种细胞因子如TNF，γ干扰素或IL-2或促凝血剂化合物的治疗。 治疗增加内源性，局部水平的细胞因子，如TNF。 当提供增强细胞因子对肿瘤活性的治疗，例如使用烷化剂，多柔比星，卡铂，顺铂和紫杉醇的治疗时，这提供了改善效果的基础。 或者，超单位治疗可以与局部化疗，全身化学疗法和/或辐射结合。

    METHOD AND SYSTEM TO REMOVE SOLUBLE TNFR1, TNFR2, AND IL2 IN PATIENTS
    4.
    发明申请
    METHOD AND SYSTEM TO REMOVE SOLUBLE TNFR1, TNFR2, AND IL2 IN PATIENTS 审中-公开
    方法和系统移除可溶性TNFR1，TNFR2和IL2患者

    公开(公告)号：US20110129441A1

    公开(公告)日：2011-06-02

    申请号：US12854385

    申请日：2010-08-11

    申请人： M. Rigdon Lentz

    发明人： M. Rigdon Lentz

    IPC分类号： A61K38/20 ,  A61K39/395 ,  A61P37/04 ,  B01D15/08

    CPC分类号： A61K39/3955 ,  A61F7/00 ,  A61K38/191 ,  A61K38/2013 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61M1/34 ,  A61M1/3406 ,  A61M1/3472 ,  A61M1/3482 ,  A61M1/3486 ,  A61M1/3489 ,  A61M1/3679 ,  A61M1/3689 ,  A61N5/10 ,  B01J20/00 ,  C07K14/525 ,  C07K14/55 ,  C07K16/2866 ,  C07K16/2878 ,  C07K17/00 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/76

    摘要： A method, and system, to induce remission in diseases characterized by excess production of sTNR and interleukin 2 has been developed. In the most preferred embodiment, the system consists of antibodies to sTNFR1, sTNFR2 and sIL2R immobilized in a column containing a material such as SEPHAROSE™. The patient is connected to a pheresis machine which separates the blood into the plasma and red cells, and the plasma is circulated through the column until the desired reduction in levels of sTNFR1, sTNFR2, and IL2 is achieved, preferably to less than normal levels. In the preferred method, patients are treated three times a week for four weeks. This process can be repeated after a period of time. Clinical studies showed reduction in tumor burden in patients having failed conventional chemotherapy and radiation treatments.

    摘要翻译： 已经开发了以sTNR和白细胞介素2过量产生为特征的疾病诱导缓解的方法和系统。 在最优选的实施方案中，该系统由固定在含有诸如SEPHAROSE TM的材料的柱中的sTNFR1，sTNFR2和sIL2R的抗体组成。 患者连接到将血液分离成血浆和红细胞的血液分离机，血浆循环通过柱直到达到期望的sTNFR1，sTNFR2和IL2水平的降低，优选达到小于正常水平。 在优选的方法中，将患者每周治疗三次，持续四周。 这个过程可以在一段时间后重复。 临床研究表明，常规化疗和放射治疗失败的患者的肿瘤负荷减少。

    METHOD AND COMPOSITIONS FOR TREATMENT OF CANCERS
    5.
    发明申请
    METHOD AND COMPOSITIONS FOR TREATMENT OF CANCERS 审中-公开
    用于治疗癌症的方法和组合物

    公开(公告)号：US20150231178A1

    公开(公告)日：2015-08-20

    申请号：US14498605

    申请日：2014-09-26

    申请人： M. Rigdon Lentz

    发明人： M. Rigdon Lentz

    IPC分类号： A61K35/14 ,  A61N5/10 ,  A61M1/36 ,  A61K35/16 ,  A61K31/454

    CPC分类号： A61K35/14 ,  A61K31/00 ,  A61K31/337 ,  A61K31/454 ,  A61K31/555 ,  A61K31/704 ,  A61K35/16 ,  A61K38/18 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/196 ,  A61K41/00 ,  A61K41/0019 ,  A61M1/34 ,  A61M1/342 ,  A61M1/3441 ,  A61M1/3472 ,  A61M1/3482 ,  A61M1/3603 ,  A61M1/3681 ,  A61M2202/0417 ,  A61M2205/50 ,  A61M2205/75 ,  A61N5/10 ,  A61N5/1028 ,  B01D15/00 ,  B01D29/50 ,  B01D37/00 ,  B01D61/02 ,  A61K2300/00

    摘要： A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF. This provides a basis for an improved effect when combined with any treatment that enhances cytokine activity against the tumors, for example, treatments using alkylating agents, doxyrubicin, carboplatinum, cisplatinum, and taxol. Alternatively, the ultrapheresis treatment can be combined with local chemotherapy, systemic chemotherapy, and/or radiation.

    摘要翻译： 一种治疗癌症的方法是使用超级血液分离法，精制以除去小于120,000道尔顿分子量的化合物，然后施用替代液，以刺激患者的免疫系统攻击实体瘤。 在优选实施例中，使用孔径为0.02至0.05微米，分子量截留值为120,000道尔顿的毛细管超滤器将患者超薄，足以过滤一个血液体积。 优选的替代液体是超分离的正常血浆。 患者优选每天治疗三周，进行诊断测试以证实肿瘤已经收缩，然后重复治疗方案。 治疗优选与替代疗法组合，例如用抗血管生成化合物，一种或多种细胞因子如TNF，γ干扰素或IL-2或促凝血剂化合物的治疗。 治疗增加内源性，局部水平的细胞因子，如TNF。 当提供增强细胞因子对肿瘤活性的治疗，例如使用烷化剂，多柔比星，卡铂，顺铂和紫杉醇的治疗时，这提供了改善效果的基础。 或者，超单位治疗可以与局部化疗，全身化学疗法和/或辐射结合。

    METHOD AND COMPOSITIONS FOR TREATMENT OF CANCERS
    8.
    发明申请
    METHOD AND COMPOSITIONS FOR TREATMENT OF CANCERS 审中-公开
    用于治疗癌症的方法和组合物

    公开(公告)号：US20100285044A1

    公开(公告)日：2010-11-11

    申请号：US12685307

    申请日：2010-01-11

    申请人： M. Rigdon Lentz

    发明人： M. Rigdon Lentz

    IPC分类号： A61K39/00 ,  A61M1/34 ,  A61M37/00 ,  A01N1/02 ,  A61K38/18 ,  A61K31/454

    CPC分类号： A61K35/14 ,  A61K31/00 ,  A61K31/337 ,  A61K31/454 ,  A61K31/555 ,  A61K31/704 ,  A61K35/16 ,  A61K38/18 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/196 ,  A61K41/00 ,  A61K41/0019 ,  A61M1/34 ,  A61M1/342 ,  A61M1/3441 ,  A61M1/3472 ,  A61M1/3482 ,  A61M1/3603 ,  A61M1/3681 ,  A61M2202/0417 ,  A61M2205/50 ,  A61M2205/75 ,  A61N5/10 ,  A61N5/1028 ,  B01D15/00 ,  B01D29/50 ,  B01D37/00 ,  B01D61/02 ,  A61K2300/00

    摘要： A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF. This provides a basis for an improved effect when combined with any treatment that enhances cytokine activity against the tumors, for example, treatments using alkylating agents, doxyrubicin, carboplatinum, cisplatinum, and taxol. Alternatively, the ultrapheresis treatment can be combined with local chemotherapy, systemic chemotherapy, and/or radiation.

    摘要翻译： 一种治疗癌症的方法是使用超级血液分离法，精制以除去小于120,000道尔顿分子量的化合物，然后施用替代液，以刺激患者的免疫系统攻击实体瘤。 在优选实施例中，使用孔径为0.02至0.05微米，分子量截留值为120,000道尔顿的毛细管超滤器将患者超薄，足以过滤一个血液体积。 优选的替代液体是超分离的正常血浆。 患者优选每天治疗三周，进行诊断测试以证实肿瘤已经收缩，然后重复治疗方案。 治疗优选与替代疗法组合，例如用抗血管生成化合物，一种或多种细胞因子如TNF，γ干扰素或IL-2或促凝血剂化合物的治疗。 治疗增加内源性，局部水平的细胞因子，如TNF。 当提供增强细胞因子对肿瘤活性的治疗，例如使用烷化剂，多柔比星，卡铂，顺铂和紫杉醇的治疗时，这提供了改善效果的基础。 或者，超单位治疗可以与局部化疗，全身化学疗法和/或辐射结合。

    Method and system for removing immunosuppressive components from the blood of mammals
    10.
    发明授权
    Method and system for removing immunosuppressive components from the blood of mammals 失效
    从哺乳动物血液中去除免疫抑制成分的方法和系统

    公开(公告)号：US4708713A

    公开(公告)日：1987-11-24

    申请号：US671990

    申请日：1984-11-16

    申请人： M. Rigdon Lentz

    发明人： M. Rigdon Lentz

    IPC分类号： A61M1/34 ,  A61M1/36 ,  A61M5/14 ,  A61M37/00

    CPC分类号： A61M1/34 ,  A61M1/3448 ,  A61M1/3482

    摘要： The invention relates to a method and system for extracorporeally treating the blood of a patient having diseased tissue or a condition, such as cancer, which results from or depends upon a dysfunction of the patient's immune system. In accordance with the invention, blood is withdrawn from the pateint, a low molecular weight fraction of the blood containing immunosuppressive components which retard or prevent immune system responses is selectively separated from the withdrawn blood, preferably by means of an ultrafilter, and treated blood is returned to the patient to initiate an immune response.

    摘要翻译： 本发明涉及一种用于体外治疗患有病变组织或病症（例如癌症）的患者的血液的方法和系统，其由患者的免疫系统的功能障碍导致或取决于患者的免疫系统的功能障碍。 根据本发明，从血液中抽出血液，优选通过超滤器选择性地从抽取的血液中选择性地分离出含有免疫抑制成分的含血免疫抑制成分的低分子量级分，其阻止或预防免疫系统反应，并且处理的血液是 返回病人发起免疫反应。